Versor Investments LP Acquires Shares of 1,597 Medpace Holdings, Inc. $MEDP

Versor Investments LP acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 1,597 shares of the company’s stock, valued at approximately $487,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Whittier Trust Co. lifted its holdings in shares of Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after buying an additional 35 shares in the last quarter. Colonial Trust Co SC lifted its holdings in shares of Medpace by 150.0% during the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company’s stock worth $58,000 after buying an additional 105 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in shares of Medpace during the first quarter worth $60,000. Assetmark Inc. lifted its holdings in shares of Medpace by 24.9% during the first quarter. Assetmark Inc. now owns 216 shares of the company’s stock worth $66,000 after buying an additional 43 shares in the last quarter. Finally, True Wealth Design LLC lifted its holdings in shares of Medpace by 52.7% during the fourth quarter. True Wealth Design LLC now owns 258 shares of the company’s stock worth $86,000 after buying an additional 89 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Medpace

In other news, CFO Kevin M. Brady sold 12,000 shares of the business’s stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $454.23, for a total transaction of $5,450,760.00. Following the sale, the chief financial officer directly owned 6,000 shares in the company, valued at approximately $2,725,380. The trade was a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Jesse J. Geiger sold 41,801 shares of the business’s stock in a transaction dated Thursday, July 24th. The stock was sold at an average price of $453.11, for a total value of $18,940,451.11. Following the sale, the president owned 36,503 shares in the company, valued at approximately $16,539,874.33. This trade represents a 53.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 112,788 shares of company stock valued at $51,018,354. Corporate insiders own 20.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MEDP. Robert W. Baird lifted their target price on Medpace from $313.00 to $490.00 and gave the stock a “neutral” rating in a report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft lifted their target price on Medpace from $270.00 to $430.00 and gave the stock a “hold” rating in a report on Wednesday, July 23rd. Mizuho lifted their target price on Medpace from $328.00 to $510.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Barclays lifted their target price on Medpace from $300.00 to $450.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 23rd. Finally, William Blair reaffirmed a “market perform” rating on shares of Medpace in a research note on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $406.60.

Medpace Stock Up 0.8%

Medpace stock opened at $465.72 on Thursday. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $501.30. The business’s 50-day moving average price is $372.56 and its two-hundred day moving average price is $333.62. The stock has a market cap of $13.08 billion, a PE ratio of 34.63, a P/E/G ratio of 2.91 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.10. The company had revenue of $603.31 million for the quarter, compared to analysts’ expectations of $537.70 million. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The business’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same period in the previous year, the business posted $2.75 earnings per share. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.